Autologous hematopoietic stem cell transplantation in systemic sclerosis patientss

Eleftherios Pelechas* and Panagiota Karagianni

Published: 27 February, 2020 | Volume 4 - Issue 1 | Pages: 001-002

ystemic sclerosis (SScl) is an autoimmune disorder of unknown aetiology, characterised by fibrosis and microvascular injury of the affected organs. The hallmark of the disease is thickening and tightness of the skin and the subcutaneous tissue. SScl can affect virtually any organ systems, most importantly the skin, blood vessels, lungs, kidneys, gastrointestinal tract, and the heart [1].

Read Full Article HTML DOI: 10.29328/journal.jsctt.1001019 Cite this Article Read Full Article PDF


Autologous hematopoietic stem cell transplantation; Systemic sclerosis; Autoimmunity; Immunosuppression


  1. Pelechas E, Kaltsonoudis E, Voulgari PV, Drosos AA. Illustrated handbook of rheumatic and musculo-skeletal diseases. Springer. 2019; 167-194.
  2. Sgantzos M, Tsoucalas G, Karamanou M, Giatsiou S, Tsoukalas I, et al. Hippocrates on Pediatric Dermatology. Pediatr Dermatol. 2015; 32: 600-603. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26058689
  3. Sinha D, Ghosh A. Scleroderma mimicker – Eosinophilic fasciitis. Indian J Rheumatol. 2017; 12: 180-184.
  4. Drosos AA, Pelechas E, Voulgari PV. Rheumatoid Arthritis Treatment. A back to the drawing board project or high expectations for low unmet needs? J Clin Med. 2019; 8: E1237. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31426398
  5. Kaltsonoudis E, Pelechas E, Voulgari PV, Drosos AA. Unmet needs in the treatment of rheumatoid arthritis. An observational study and a real-life experience from a single university center. Semin Arthritis Rheum. 2019; 48: 597-602. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30075990
  6. Tyndall A, Gratwohl A. Blood and marrow stem cell transplants in auto-immune disease: a consensus report written on behalf of the European League against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 1997; 19: 643-645. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9156239
  7. Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomized phase 2 trial. Lancet. 2011; 378: 498-506. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21777972
  8. van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014; 311: 2490-2498. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25058083
  9. Shouval R, Furie N, Raanani P, Nagler A, Gafter-Gvili A. Autologous hematopoietic stem cell transplantation for Systemic Sclerosis: A systematic review and meta-analysis. Biol Blood Marrow Transplant. 2018; 24: 937-944. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29374527
  10. Pawlak-Bus K, Schmidt W, Olejarz M, Czyz A, Komarnicki M, et al. Autologous hematopoietic stem cell transplant for progressive diffuse systemic sclerosis: procedural success and clinical outcome in 5-year follow-up. Reumatologia. 2019; 57: 50-54. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30858631
  11. Sullivan KM, Majhail NS, Bredeson C, Carpenter PA, Chatterjee S, et al. Systemic sclerosis as an indication for autologous hematopoietic cell transplantation: position statement from the American society for blood and marrow transplantation. Biol Blood Marrow Transplant. 2018; 24: 1961-1964. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29953945

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More